Gothenburg, January 5, 2021 - Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company that develops next generation immuno-oncological treatments based on enhanced oncolytic viruses and CAR T-cells, today announced that it has acquired patent US 9,017,672 B2 – a viral vector used in its candidate ELC-100 – from Immunicum. The transfer of the patent amounts to a total of 250,000 EUR in payments, excluding potential milestones. The acquisition further strengthens the IP protection of ELC-100, Elicera’s most advanced project.
The patent for the viral vector used in ELC-100 is currently owned by Immunicum and out licensed to Elicera. The remuneration for the transfer of the patent from Immunicum to Elicera is an upfront payment of 175,000 EUR with an additional annual payment of 25,000 EUR over the next three years, excluding potential milestone payments according to the terms of the agreement in connection to conclusion of future clinical studies.
The agreement further states that Elicera will grant a world-wide non-exclusive license to Immunicum for the purpose of using the viral vector to label immune cells or tumor cells with exogenous antigens for therapeutic purposes. Elicera’s ownership of the patent also opens up future opportunities to create new oncolytic viruses based on the same virus vector.
Any prior agreements with Immunicum, including mutual royalties, have been terminated.
– A strong patent portfolio for our clinical development program is of highest strategic importance, and the acquirement of the patent for the viral vector used in ELC-100, our most advanced project, gives us full control over the candidate’s IP protection. It will also facilitate negotiations with potential partners for ELC-100, said Jamal El-Mosleh, CEO of Elicera.
Elicera's oncolytic virus ELC-100 is based on a genetically modified adenovirus that has been optimized with regards to its ability to selectively infiltrate and replicate in neuroendocrine cancer cells but not in healthy cells. When new virus particles have formed in enough numbers, the tumor cells burst through a so-called immunogenic oncolysis. ELC-100 is currently being used in an ongoing clinical phase I/II-study in the treatment of neuroendocrine tumors.
For further information please contact:
Jamal El-Mosleh, CEO, Elicera Therapeutics AB
Phone: +46 (0) 703 31 90 51
About Elicera Therapeutics AB
Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses. In addition, Elicera has developed a technology platform called iTANK that can be used to optimize all CAR T cells in development and activate killer T cells against cancer. The Company’s share (ELIC) is traded on Nasdaq First North Growth Market. G&W Fondkommission has been appointed the Company's Certified Adviser. E-mail: email@example.com, tel: +468-503 000 50.
For more information, please visit www.elicera.com